✦ LIBER ✦

C20 Selected molecular markers of tumour tissue and their use in predicting the efficacy of targeted therapy of metastatic renal cell carcinoma

✍ Scribed by Trávníček, I.; Hora, M.; Stránský, P.; Hes, O.; Branžovský, J.; Holubec, L.

Book ID: 123294796
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 131 KB
Volume: 12
Category: Article
ISSN: 1569-9056
DOI: 10.1016/S1569-9056(13)61868-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Key considerations in patient selection

Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma

✍ Alain Ravaud 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 505 KB

442 ROLE OF MOLECULAR MARKERS IN NEPHREC

442 ROLE OF MOLECULAR MARKERS IN NEPHRECTOMY SPECIMEN AS PROGNOSTICATORS FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN THE ERA OF TARGETED THERAPY

✍ You, Dalsan; Cho, Yong Mee; Lee, Jae-Lyun; Song, Cheryn; Hong, Jun Hyuk; Kim, Ch 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 139 KB

313 Role of molecular markers in nephrec

313 Role of molecular markers in nephrectomy specimen as prognosticators for patients with metastatic renal cell carcinoma in the era of targeted therapy

✍ D. You; Y.M. Cho; J.H. Ahn; D.H. Lee; J.L. Lee; J.H. Hong; C.S. Kim; H. Ahn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Course of size and density of metastatic

Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy

✍ Hittinger, Markus; Staehler, Michael; Schramm, Nicolai; Übleis, Christopher; Bec 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 619 KB

740 TUMOR GROWTH RATE SHOULD BE APPLIED

740 TUMOR GROWTH RATE SHOULD BE APPLIED IN THE DEFINITION OF PROGRESSION DISEASE DURING MOLECULAR TARGETED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ Zhang, Hai-Liang; Ye, Ding-Wei 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 44 KB

Comparative efficacy of vascular endothe

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

✍ Kwonoh Park, Jae-Lyun Lee, Inkeun Park, Seongjoon Park, Yongcheol Ahn, Jin-Hee A 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 193 KB